BioMarin Pharmaceuticals BMRN AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's AFS securities?
- BioMarin Pharmaceuticals (BMRN) reported AFS securities of $0 in Q1 2026.
- How has BioMarin Pharmaceuticals's AFS securities changed year-over-year?
- BioMarin Pharmaceuticals's AFS securities decreased by 100.0% year-over-year, from $506.72M to $0.
- What is the long-term trend for BioMarin Pharmaceuticals's AFS securities?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's AFS securities has grown at a 11.5% compound annual growth rate (CAGR), from $285.47M to $492.24M.
- What does AFS securities mean?
- Investments in securities that the company holds for the long term but could sell if needed.
- How do you interpret AFS securities?
- Growth in this category reflects the company's ability to accumulate long-term capital reserves, while decreases may indicate divestment to fund operations or acquisitions.
- How does AFS securities compare across companies?
- Common in large-cap pharmaceutical companies with significant cash reserves and conservative investment policies.